tiprankstipranks
Trending News
More News >

MedPlus Subsidiary Faces Drug License Suspensions

Story Highlights
  • MedPlus operates in the healthcare industry, focusing on retail pharmacy services.
  • Optival Health Solutions faces drug license suspensions, risking Rs 3.04 lacs in revenue loss.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Confident Investing Starts Here:

MedPlus Health Services Ltd. ( (IN:MEDPLUS) ) has provided an announcement.

MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its stores. The suspensions, issued under the Drugs and Cosmetics Act, 1940, will affect stores in Andhra Pradesh and Karnataka, potentially resulting in a revenue loss of approximately Rs 3.04 lacs. These suspensions highlight regulatory challenges and could impact the company’s financial operations and market positioning.

More about MedPlus Health Services Ltd.

MedPlus Health Services Ltd. operates in the healthcare industry, primarily focusing on retail pharmacy services. The company is known for its extensive network of pharmacy stores across India, offering a wide range of pharmaceutical products and health-related services.

YTD Price Performance: -6.88%

Average Trading Volume: 6,909

Current Market Cap: 90.08B INR

For a thorough assessment of MEDPLUS stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App